Valentina Valenti1, Bríain Ó Hartaigh2, Ran Heo1, Iksung Cho1, Joshua Schulman-Marcus3, Heidi Gransar4, Quynh A Truong1, Leslee J Shaw5, Joseph Knapper5, Anita A Kelkar5, Pratik Sandesara5, Fay Y Lin6, Sebastiano Sciarretta7, Hyuk-Jae Chang8, Tracy Q Callister9, James K Min10. 1. Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and the Weill Cornell Medical College, New York, New York. 2. Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and the Weill Cornell Medical College, New York, New York; Department of Internal Medicine, Section of Geriatrics, Yale School of Medicine, New Haven, Connecticut. 3. Division of Cardiology, New York-Presbyterian Hospital and the Weill Cornell Medical College, New York, New York. 4. Department of Imaging, Cedars-Sinai Medical Center, Los Angeles, California. 5. Division of Cardiology, Emory University School of Medicine, Atlanta, Georgia. 6. Department of Medicine, Weill Cornell Medical College, New York, New York. 7. IRCCS Neuromed, Pozzilli, Italy; Department of Medical-Surgical Sciences and Biotechnologies, University of Rome "Sapienza," Latina, Italy. 8. Division of Cardiology, Severance Cardiovascular Hospital and Severance Biomedical Science Institute, Yonsei University College of Medicine, Yonsei University Health System, Seoul, South Korea. 9. Tennessee Heart and Vascular Institute, Hendersonville, Tennessee. 10. Dalio Institute of Cardiovascular Imaging, New York-Presbyterian Hospital and the Weill Cornell Medical College, New York, New York. Electronic address: jkm2001@med.cornell.edu.
Abstract
OBJECTIVES: The aim of this study was to examine the long-term prognosis in asymptomatic individuals with a coronary artery calcium (CAC) score of 0 and its associated warranty period. BACKGROUND: Emerging evidence supports a CAC score of 0 as a favorable cardiovascular short-to intermediate-term prognostic factor. METHODS: A total of 9,715 individuals undergoing CAC imaging were stratified by age, Framingham risk score (FRS), and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) categories and followed for a mean of 14.6 years (range 12.9 to 16.8 years). Cox regression, area under the receiver-operating characteristic curve, and net reclassification information were used to assess all-cause mortality, discrimination, and reclassification of a CAC score of 0 compared with the FRS and NCEP ATP III, respectively. A warranty period was pre-defined as <1% annual mortality rate. Vascular age was estimated by linear regression. RESULTS: In 4,864 individuals with a baseline CAC score of 0 (mean age, 52.1 ± 10.8 years; 57.9% male), 229 deaths occurred. The warranty period of a CAC score of 0 was almost 15 years for individuals at low and intermediate risk with no significant differences regarding age and sex. A CAC score of 0 was associated with a vascular age of 1, 10, 20, and 30 years less than the chronological age of individuals between 50 and 59, 60 and 69, 70 and 79, and 80 years of age and older, respectively. The CAC score was the strongest predictor of death (hazard ratio: 2.67, 95% confidence interval: 2.29 to 3.11) that enabled discrimination and consistent reclassification beyond the FRS (area under the receiver-operating characteristic curve: 0.71 vs. 0.64, p < 0.001) and NCEP ATP III (area under the receiver-operating characteristic curve: 0.72 vs. 0.64, p < 0.001). CONCLUSIONS: A CAC score of 0 confers a 15-year warranty period against mortality in individuals at low to intermediate risk that is unaffected by age or sex. Furthermore, in individuals considered at high risk by clinical risk scores, a CAC score of 0 confers better survival than in individuals at low to intermediate risk but with any CAC score.
OBJECTIVES: The aim of this study was to examine the long-term prognosis in asymptomatic individuals with a coronary artery calcium (CAC) score of 0 and its associated warranty period. BACKGROUND: Emerging evidence supports a CAC score of 0 as a favorable cardiovascular short-to intermediate-term prognostic factor. METHODS: A total of 9,715 individuals undergoing CAC imaging were stratified by age, Framingham risk score (FRS), and National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) categories and followed for a mean of 14.6 years (range 12.9 to 16.8 years). Cox regression, area under the receiver-operating characteristic curve, and net reclassification information were used to assess all-cause mortality, discrimination, and reclassification of a CAC score of 0 compared with the FRS and NCEP ATP III, respectively. A warranty period was pre-defined as <1% annual mortality rate. Vascular age was estimated by linear regression. RESULTS: In 4,864 individuals with a baseline CAC score of 0 (mean age, 52.1 ± 10.8 years; 57.9% male), 229 deaths occurred. The warranty period of a CAC score of 0 was almost 15 years for individuals at low and intermediate risk with no significant differences regarding age and sex. A CAC score of 0 was associated with a vascular age of 1, 10, 20, and 30 years less than the chronological age of individuals between 50 and 59, 60 and 69, 70 and 79, and 80 years of age and older, respectively. The CAC score was the strongest predictor of death (hazard ratio: 2.67, 95% confidence interval: 2.29 to 3.11) that enabled discrimination and consistent reclassification beyond the FRS (area under the receiver-operating characteristic curve: 0.71 vs. 0.64, p < 0.001) and NCEP ATP III (area under the receiver-operating characteristic curve: 0.72 vs. 0.64, p < 0.001). CONCLUSIONS: A CAC score of 0 confers a 15-year warranty period against mortality in individuals at low to intermediate risk that is unaffected by age or sex. Furthermore, in individuals considered at high risk by clinical risk scores, a CAC score of 0 confers better survival than in individuals at low to intermediate risk but with any CAC score.
Authors: Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson Journal: J Am Coll Cardiol Date: 2013-11-12 Impact factor: 24.094
Authors: John W McEvoy; Michael J Blaha; Juan J Rivera; Matthew J Budoff; Atif N Khan; Leslee J Shaw; Daniel S Berman; Paolo Raggi; James K Min; John A Rumberger; Tracy Q Callister; Roger S Blumenthal; Khurram Nasir Journal: JACC Cardiovasc Imaging Date: 2012-10
Authors: R J Gibbons; K Chatterjee; J Daley; J S Douglas; S D Fihn; J M Gardin; M A Grunwald; D Levy; B W Lytle; R A O'Rourke; W P Schafer; S V Williams Journal: Circulation Date: 1999-06-01 Impact factor: 29.690
Authors: Michael J LaMonte; Shannon J FitzGerald; Timothy S Church; Carolyn E Barlow; Nina B Radford; Benjamin D Levine; John J Pippin; Larry W Gibbons; Steven N Blair; Milton Z Nichaman Journal: Am J Epidemiol Date: 2005-08-02 Impact factor: 4.897
Authors: Kazuhiro Osawa; Rine Nakanishi; Robyn L McClelland; Joseph F Polak; Warrick Bishop; Ralph L Sacco; Indre Ceponiene; Negin Nezarat; Sina Rahmani; Hong Qi; Mitsuru Kanisawa; Matthew J Budoff Journal: Atherosclerosis Date: 2018-05-17 Impact factor: 5.162
Authors: Shaista Malik; Yanglu Zhao; Matthew Budoff; Khurram Nasir; Roger S Blumenthal; Alain G Bertoni; Nathan D Wong Journal: JAMA Cardiol Date: 2017-12-01 Impact factor: 14.676